Bio-Techne expands AI-engineered protein portfolio for cell therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
July 8, 2026 6:30 AM EDTAdvancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows
New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems AI-Engineered Designer Protein portfolioAI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows
Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing
MINNEAPOLIS, July 8, 2026 /PRNewswire/ --... More
